Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Multiple Myeloma
BIOLOGICAL: Descartes-11|DRUG: Fludarabine|DRUG: Cyclophosphamide
Number of Participants With Treatment-Related Adverse Events, Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma, Time Frame: 21 days
Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria, Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG)., Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.